Adults taking high doses of amphetamine-based medications for ADHD, such as Adderall, face a five-fold increased risk of developing psychosis or mania. The risk was highest for those taking 30 mg or more of dextroamphetamine, with 81% of psychosis or mania cases potentially avoidable by lowering the dose.
Enlarge (credit: Getty | George Frey)
While supplies of Adderall and its generic versions are finally recovering after a yearslong shortage, the Drug Enforcement Administration is now working to curb the short supply of another drug for attention-deficit/hyperactivity disorder: Vyvanse (lisdexamfetamine) and its generic versions.
This week, the DEA said it will increase the allowed production amount of lisdexamfetamine by roughly 23.5 percent, increasing the current 26,500 kg quota by 6,236 kg, for a new total of 32,736 kg. The DEA also allowed for a corresponding increase in d-amphetamine, which is needed for production of lisdexamfetamine.
"These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," the DEA said.
New research highlights a significant link between neurodivergence and chronic fatigue, suggesting that increased inflammation from childhood stress may contribute. The study emphasizes the need for better screening and support for neurodivergent children to reduce chronic fatigue risks. Findings advocate for a comprehensive approach to identify contributing factors and improve quality of life. Enhanced support systems for neurodivergent children could mitigate these risks.
Login
